You are here

Article Text

Article menu
Download PDFPDF
Editorial
Biomarkers and ST-elevation myocardial infarction
  1. Christian Mueller
  1. Correspondence to Professor Christian Mueller,
    Department of Cardiology, University Hospital Basel, Petersgraben 4, Basel CH-4031, Switzerland; chmueller{at}uhbs.ch

https://doi.org/10.1136/heartjnl-2013-303667

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In the recent Heart paper, Cuculi et al1 from Oxford University challenge two conventional wisdoms in clinical cardiology: first, biomarkers do not have a role in the management of patients presenting with suspected ST-elevation myocardial infarction (STEMI); and second, in the absence of cardiogenic shock, there is no remaining unmet clinical need in STEMI as contemporary coronary reperfusion strategies yield excellent patient outcomes.

    In their investigation, the authors report the course of plasma neuropeptide Y levels in patients undergoing successful percutaneous coronary intervention (PCI) and relate these to non-invasive and invasive measures of the success of …

    View Full Text

    Footnotes

    • Competing interests Professor Mueller has received research grants from the Swiss National Science Foundation, the European Union, the Swiss Heart Foundation, Abbott, Alere, Beckman Coulter, BRAHMS, Critical Diagnostics, Nanosphere, Roche, Siemens, 8sense, and the Department of Internal Medicine, of the University Hospital Basel, as well as speaker honoraria from Abbott, Alere, Brahms, Novartis, Roche, and Siemens.

    • Patient consent Obtained.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles